‘We can beat Ebola but must prepare for what comes next,’ says Wellcome Trust head

Jeremy Farrar, a world expert on diseases, tells of the fight against the deadly virus that spread fear this decade – and how to prepare for the health battles to comeJeremy Farrar, head of the Wellcome Trust, has a straightforward view about the way doctors and scientists tackled thecurrent Ebola epidemic in the Democratic Republic of the Congo. “In four or five years, we have taken a disease that was absolutely terrifying and which had an enormously high death rate – more than 80% – and we have turned it, potentially, into something that is preventable and treatable.”The fact this has been done in a nation in the middle of a civil war is “simply miraculous”, added Farrar, a world expert on emerging diseases. “It is a truly phenomenal achievement. If you do not celebrate that, you cannot celebrate anything else.”Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Ebola Infectious diseases Vaccines and immunisation Medical research World news Source Type: news

Related Links:

Authors: Batra S, Ochani RK, Diwan MN, Yasmin F, Qureshi SS, Bhimani S, Shaikh S, Tariq MA, Ahmed Ashraf M, Farooqi HA, Dodani SK Abstract Ebola Virus Disease (EVD), also known as Ebola Hemorrhagic Fever (EHF), initially emerged over 40 years ago in the Democratic Republic of Congo. Endemic to Africa, outbreaks have been recorded in six African countries since its detection in 1976. Fruit bats are believed to be the natural hosts of Ebola viruses (EBoV), with humans and other mammals serving as accidental hosts. Transmission of EBoV has been reported in various ways, including human to human transmission through cl...
Source: Infezioni in Medicina - Category: Infectious Diseases Tags: Infez Med Source Type: research
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
The COVID-19 pandemic has had significant global consequences, with healthcare systems stretched to their limits, a growing death toll, and economic devastation as economies came grinding to a halt. The pandemic and its aftereffects will be with u...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Public Health Source Type: blogs
An infectious outbreak can conclude in more ways than one, historians say. But for whom does it end, and who gets to decide?
Source: NYT Health - Category: Consumer Health News Authors: Tags: Epidemics Coronavirus (2019-nCoV) Plague Smallpox Ebola Virus Influenza Epidemic (1918-19) Rats Antibiotics Bubonic Plague Fleas Microbiology Deaths (Fatalities) Vaccination and Immunization your-feed-science your-feed-health Source Type: news
In just a few months, the COVID-19 pandemic has crossed borders and oceans, killing thousands, sickening millions, and forcing millions more to reckon with the economic and personal chaos of closures and lockdowns. Yet as the global infection count rises, the crisis has also given rise to acts of ingenuity. The pandemic has set off a global race for both an effective vaccine and for the accurate, rapid-response tests that will be necessary before workplaces can safely reopen. Vaccines and tests are essential, but they’re not the only front on which to combat the virus. In the face of an urgent threat, scientists have...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized COVID-19 Source Type: news
Abstract With the dramatic background of a newly emerged virus (SARS-CoV-2) spreading around the world, Coronavirus and other infectious health threats for the human and animal populations were illustrated and debated in excellent presentations at the IABS meeting 26-28 of February 2020. Historical evidence of pandemics and lessons learned from recent epidemics or epizootics caused by many pathogens (e.g., Ebola, Zika, and African Swine Fever viruses) illustrated the overarching need for close international cooperation. New and old technologies in vaccine development and their use were presented, resulting in a ca...
Source: Biologicals : Journal of the International Association of Biological Standardization - Category: Biotechnology Authors: Tags: Biologicals Source Type: research
CONCLUSIONThe pre ‐​COVID‐​19 research is unanimous that governments cannot expect to rely on travel restrictions to prevent the spread of pandemics similar to influenza. Travel restrictions do not prevent the spread of disease and may only delay it for a few days or weeks if implemented prior to the interna tional transmission of the disease. The Trump administration’s travel restrictions waited until after the virus had already entered the United States, and they exempted many travelers from China, not to mention the rest of the world.[30]The research shows that the Trump administration should have kno...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.  George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,&r...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
Until we end COVID-19 transmission across the planet, we are likely to keep getting multiple COVID-19 “waves”— that is, rolling, recurrent outbreaks. While no public health expert has a foolproof crystal ball, this scenario of repeated waves means that the likely contours of the next one to two years are now coming into clearer view. Right now, many countries including Italy, Spain, the United States, and the United Kingdom, are still struggling desperately to put out the initial fire. They are using suppression measures like stay-at-home orders as a fire extinguisher to smother transmission while urgentl...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Congo Health | Ebola | Ebola Vaccine | Epidemics | Epidemiology | Infectious Diseases | Research | Science | Vaccines